Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann

Tracy Staton It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to ...

Daiichi Sankyo lays out road map for Ranbaxy deal with Sun

Eric Palmer Daiichi Sankyo today released its road map for the $ 3.2 all-stock Ranbaxy deal with Sun Pharmaceutical and the mile markers it sees to completion. It also provides some ...

GSK, J&J, TPI want Australia to ease their pain on poppy supplies

Eric Palmer Australia accounts for nearly half of the global supply of opium poppy plants that produce the ingredients needed for pain drugs. But drugmakers are in the midst of a political ...

Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck antibiotic

Damian Garde Durham, NC's Scynexis is queuing up for a $ 55 million IPO, looking to ride the wave of biotech bullishness and raise cash for its in-development anti-infective. FierceBiotech ...

Activist Denner gets his way with a board seat at troubled Ariad

Carly Helfand Alex Denner has taken a seat with the board of directors at Ariad–a position he demanded back in October when the company's only approved drug, Iclusig, ran ...

Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Tracy Staton Indian drugmakers have a shot at bringing Gilead Sciences' hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" ...

Aveo’s cancer drug circles the drain after a scuttled Phase II trial

Damian Garde Aveo Oncology and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced. FierceBiotech ...

Bristol-Myers says it’s open to dealmaking in the cancer field

Emily Mullin Bristol-Myers Squibb says it's on the lookout for new deals, but that its focus will be on snapping up experimental treatments still in development instead of commercial ...

Drug buyers sue Novo Nordisk over ‘wrongful’ delays to diabetes generic

Carly Helfand The Federal Trade Commission may now have the right to challenge pay-for-delay deals, but drugmakers can still stall the launches of competing generic products. And that's ...

Former Bristol-Myers R&D chief signs on at VC firm

Tracy Staton Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew. FiercePharma News

UPDATED: FDA OKs AstraZeneca’s long-delayed diabetes drug dapagliflozin

John Carroll The FDA has handed AstraZeneca a green light to begin marketing dapagliflozin, its long-delayed SGLT2 diabetes drug, which will now try to defy ...

Threshold Pharmaceuticals Achieves Target Enrollment in Phase III Sarcoma Trial

barbara.lempert Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma $ 12.5 Million USD ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS